Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5443_Библиотеки_им_академика_М_И_Перельмана
.pdf
4.1.3 CADD simulations in pharmacokinetic functions
There have been many developed and effectively used in vitro high-throughput
ADMET property screening tests [27]. Caco-2 and Madin-Darby canine kidney (MDCK)
cell monolayers are commonly employed as models to assess membrane permeability
and estimate in vitro absorption. The continually expanding computer capability and
significant improvements in in silico medicine algorithms have spurred the develop-
ment of numerous computational programs with the goal of modeling drug ADMET
properties [28]. In princip le, high-throughput screening and structure-based techni-
ques share a common characteristic in that they both consider the significance of tar-
get and ligand structural information. Pharmacophore identification, ligand design,
and ligand docking represent prominent instances of structure-based methodologies
[29]. The article provides coverage of the theoretical foundations of the most promi-
nent approaches and currently effective implementations. Ligand-based techniques
only rely on ligand information to make predictions regarding activity, mostly by as-
sessing the degree of similarity or dissimilarity between a given ligand and known
active ligands. These technologies include target/ligand databases, homology model-
ing, and ligand fingerprint approaches. Ultimately, this study employs successful in-
stances from the existing body of research to examine computational approaches for
predicting toxicity and optimizing physiological characteristics [30].
4.1.4 Pharmacophore modeling in oral drug delivery
The structural prerequisites for interactions between medications and the targets im-
plicated in the ADMET process are examined using pharmacophore modeling and
flexible docking studies, which employ a quantitative methodology. If the target is
well-known, a study of the pharmacophores of a collection of medications transported
by a transporter would reveal the minimal structural requirements for transport
[31, 32].
Recent research has examined drug development using flexible docking methods.
The primary interactions in either research can be utilized to test drugs for ADMET [33].
Ligand structure information
QSAR
Pharmacophore Modelling
Ligand based virtual screening
Figure 4.1: Ligand-based drug design.
4 Computer-aided pharmacokinetic functions 73
https://t.me/med1917
4.1.5 Quantitative structure–activity relationship
Thequantitativestructure–activity connection represents a quantitative approach.
This word means quantitative structure–property connection. Studies link molecular
descriptors to ADMET traits using multivariate analysis [34].
Drug structure reveals many molecular characteristics.
Molecular descriptors must precisely reflect the interactions that produce the de-
sired biological features. The correct mathematical tool is needed for ADMET modeling,
however it is sometimes possible to compare statistical methods to choose the best one.
Quantitative structure–activity relationship’s (QSAR) capacity to discover novel
chemical compounds’ characteristics without producing or testing them offers major
advantages [35]. Studies also relate them to material structure, biological processes,
and physiological traits.
QSAR method basics: QSAR is useful for modeling biological activities and absorp-
tion, distribution, metabolism, and excretion (ADME)/Tox characteristics.
4.1.6 QSAR modeling
1. Gather as much physicochemical information as you can on the dru gs that are
chosen for testing.
2. If there are many descriptor variables being used, try removing some of them be-
fore modeling.
3. Choose a variable selection approach that is suitable for the problem.
4. Decide on a modeling strategy that is appropriate for the data and data collection
that will be modeled. It is advisable to employ simple modeling techniques [36].
5. Predictive power should be taken into account in addition to goodness of fit (sta-
tistical quality) when evaluating models.
4.1.7 Software used in pharmacokinetic functions
for extravascular route for oral drug delivery
PK modeling is needed to quantify the dose–concentration relationship and under-
stand drug concentration time courses following different formulations [37].
The following graph denotes the decrease in the toxicities in the oral dosage form
before computer-aided simulations and after (Figures 4.2 and 4.3, (Table 4.1)).
The PK functions contributing to drug failure decreased after the CADD simulations.
74 Sunil Kumar Kadiri, Dhritija Sathavalli, and Prashant Tiwari
https://t.me/med1917
The pharmacokinetics in oral drug delivery is as follows:
D
B
V
D
Absorption
Elimination
D
B
D
E
The drug release profile can be adjusted to increase drug half-life and target site
accumulation.
Computer-aided PK approaches are frequently used to analyze exposure-response
correlations, quantify drug disposition and pharmacological effects, and forecast
safety and efficacy results.
Modeling and simulation during drug development can improve preclinical and
clinical research design and interpretation. When biological under standing is solid,
39%
30%
11%
10%
5%
PK
Efficacy
Animal toxicity
ADR
Commercial
Figure 4.2: PK before CADD simulations.
14%
43%
36%
1.2
PK
Toxicity
Efficacy
Other
Figure 4.3: PK after CADD simulations.
4 Computer-aided pharmacokinetic functions 75
https://t.me/med1917
mechanism-based techniques provide quantitative comparisons among candidates to
support scientific findings. Medication development will improve using this technology.
4.1.8 GastroPlus software
We first built GastroPlus to estimate oral drug absorption. A CAT model underpins the fore-
casts’ theory and model [38]. This model compartmentalizes the small intestine to match
transit time data. Differential equations were used to quantify absorption by accounting
for drug in solution, permeability, and compartment drug transit. A compartmental PK
model was introduced to the CAT model to simulate plasma concentration–time profiles.
Based on this first general model, we were able to develop the more sophisticated ACAT
model for use in GastroPlus (Figure 4.4). We looked at issues including solubility, re-
lease from dosage forms, absorption in the stomach and colon, lumen degradation, and
regional considerations such intestinal metabolism and transport to better comprehend
drug manufacturing. Compartmental PK is used to model the time-dependent plasma
concentration. This application mimics oral drug absorption and time. Information
modeling, tissue distribution and clearance simulation, and extrapolation of in vitro
drug dissolution data to in vivo absorption are all possible with the In Vitro – in vivo
(IVIV) module [39]. By adapting simulation parameters to experimental data, the model-
ing module may optimize model parameters. These “optimized” models can simulate
related molecules or better describe a drug. This module lets the formulation be modi-
Figure 4.4: ACAT model and GastroPlus software.
76 Sunil Kumar Kadiri, Dhritija Sathavalli, and Prashant Tiwari
https://t.me/med1917
fied to fit a plasma concentration–time profile after a good match. Finally, it lets users
evaluate Pharmacodynamic (PD) parameters and fit standard PD models to experimen-
tal data. GastroPlus excels in oral absorption forecasting and formulation optimization.
For common preclinical toxicological and pharmacology species, it has ACAT physiolog-
ical models. Absorption simulations using PK parameter point estimates are supported
by GastroPlus, but population variability predictions are not [40]. This user-defined un-
predictability is understandable.
4.1.9 Application of Simcyp to human ADME prediction
Preclinical drug research increasingly makes use of in vitro data from human tissues
and animal models to simulate and predict human PK functions. The Food and Drug
Administration, for example, uses critical path initiatives, which advocates for the use
of quantitative PK in the study of drug candidates and the development of appropri-
ate dosing strategies. Increases in both therapeutic success rates and research costs
are possible. Procedures are sped up via simulation and modeling [41].
The population results and risk assessments it gives are above-average. Involve-
ment of CYP enzymes in paroxetine metabolism has been identified using population-
based modeling. Choose suitable CYP3A4 probe substrates for clinical drug interaction
studies using in vitro and in vivo data with Simcyp simulator. Human clinical trials
with reduced CYP3A have been employed with Simcyp’s PK modeling to investigate
UGT1A4’s role in midazolam metabolism.
4.2 Computer-aided pharmacokinetic functions
in oral drug delivery system
PK is a quantitative examination of the progression of pharmacological ADME mecha-
nisms. The field of PK studies how medicines travel through the body. A fundamental
principle of PK is that a drug’s toxicity and desired therapeutic response are both
functions of its concentration in the body. The maintenance of the medicine is fre-
quently essential for effective pharmacotherapy. Concentrations that are effective
and safe fall within a specified range of an effective therapeutic index.
These in vivo PK techniques are only applicable to a small subset of compounds,
and thus might not be helpful for screening a large number of drugs (Figure 4.5).
Some businesses administer five to six chemicals in animals at once via cassette dos-
ing, although these models typically yield inaccurate PK data mostly because of Drug-
drug interactions (DDIs) [42].
The most popular drug delivery method is oral administration since it is conve-
nient and has high patient compliance.
4 Computer-aided pharmacokinetic functions 77
https://t.me/med1917
Figure 4.5: In silico software in pharmacokinetic functions.
78 Sunil Kumar Kadiri, Dhritija Sathavalli, and Prashant Tiwari
https://t.me/med1917
Oral drugs should cross intestinal barriers and enter the portal bloodstream. Biomem-
branes are lipid bilayers with hydrophilic ends and interiorized lipid layers. Membrane
protein interactions on contact surfaces are involved in various biological processes, in-
cluding metabolism, trafficking, signaling, host-pathogen interactions, and transmem-
brane transport [43]. One cell’s tight connections generate small aqueous holes. Watery
poresmakeup0.01%ofthesmallintestine’s surface. Drug candidates may permeate bi-
layers depending on characteristics. Many drug transporters in the digestive tract’s efflux
and uptake systems impact medicine absorption. Most drug research uses Caco-2 cells;
however PAMPA was employed early on. If P-glycoprotein (P-gp), breast cancer resistance
protein (BCRP), or multidrug resistance-associated protein 2 (MRP2) are suspected to be
involved in the efflux of a new chemical entity (NCE), or if LLC-PK cell assays are con-
ducted, then Caco-2 bidirectional permeability experiments should also be performed to
thoroughly evaluate the involvement of these transporters.
4.3 Drug absorption
Oral medication delivery is easy and patient-compliant, making it the most preferred
approach. In silico methods focus on modeling medication oral absorption, which oc-
curs in the human gut. Bioavailability and absorption depend on medication solubility
and intestinal permeability.
4.3.1 Solubility
– Most intestinal lumen-absorbed drugs must disintegrate. Direct milligram-scale
solubility measurement is expensive and time-consuming.
– Applying the “ general solubility equation” to a drug’slogP value and melting
point might indirectly estimate its solubility. Chemical solubility may be predicted
before synthesis using in silico modeling.
– Other approaches added terms to log values to predict solute crystal lattice en-
ergy’s solubility effect.
– QSPR links molecular properties to solubility via multivariate research.
4.3.2 Intestinal permeation
Both passive diffusion and active transport play a role in the process, making it com-
plicated and hard to predict based on chemical mechanism alone. As a result, modern
models attempt to recreate in vitro the permeability of the Caco-2, MDCK, or PAMPA
4 Computer-aided pharmacokinetic functions 79
https://t.me/med1917
membranes, all of which have proven to be useful indicators of drug absorption
in vivo (Figure 4.6) [44, 45].
Drug efflux transporters return absorbed drugs to the gut lumen. P-gp, MRP, and
BCRP are examples. GastroPlus and other commercial tools predict oral absorption
and other PK.
Figure 4.6: Ligand-based drug design and structure-based drug design.
80 Sunil Kumar Kadiri, Dhritija Sathavalli, and Prashant Tiwari
https://t.me/med1917
4.3.3 Drug distribution
Drug delivery frequency is determined by V
d
, the relative partitioning of a drug be-
tween plasma concentration and tissue, and other characteristics.
Due to the absence of in vivo data and process complexity, computational models
that predict V
d
using computed descriptors are being developed.
4.3.4 PPB (Plasma Protein Binding) or protein binding
Drugs attach to plasma proteins like serum albumin because unbound drug adequacy
determines pharmacological efficacy. PPB (Plasma Protein Binding) must be con sid-
ered when determining effective (unbound) drug plasma concentration. When mea-
suring powerful (unbound) drug plasma, PPB must be considered.
4.3.5 BBB (blood–brain barrier)
The blood–brain barrier (BBB) controls the extracellular environment of the central
nervous system. Monitoring BBB medication penetration is essential for drug develop-
ment [46].
4.3.6 Excretion
– Measures drug clearance by plasma volume cleared without drug per unit time.
– Calculates drug half-life using V
d
to determine dose. Plasma is cleared mostly by
the liver and kidneys.
– Drug structures alone cannot predict plasma clearance.
In vitro data is used to estimate in vivo clearance in current modeling research.
As with other PK, active transporters complicate hepatic and renal clearance.
4.3.7 Active transporters
Any ADMET modeling method should include transporters due to their pervasiveness
on barrier membranes and chemical overlap between many drugs.
Despite extensive in vitro data on these transporters, which has enabled the
building of pharmacophore and QSAR models for many, most prediction algorithms
do not include active transport.
4 Computer-aided pharmacokinetic functions 81
https://t.me/med1917
These models simplify complicated transporter-drug absorption, distribution, and
excretion interactions. Their use in modeling systems may enhance drug disposition
behavior predictions [47].
4.3.8 BBB–choline transporter
The structurally varied group of chemicals that were found to be significant for
BBB–choline transporter recognition was used to build the 3D-QSAR models [48–50].
4.4 Conclusion
The success rate of CADD in oral drug delivery system has shown its value in the PK
process. CADD provides information about the target molecules, lead compounds,
screening and optimization. It also aids in the efficient functioning of the ADME pro-
cess through various software like GastroPlus, and various approaches like QSAR,
ACAT modeling, pharmacophore modeling, Simcyp, and other tools contribute to bet-
ter understanding of the PK of the oral drug delivery system.
References
[1] Zou, H., Banerjee, P., Leung, S. S., & Yan, X. Application of pharmacokinetic-pharmacodynamic
modeling in drug delivery: Development and challenges. Frontiers in Pharmacology, 2020 Jul 3,
11, 997.
[2] Kanwal, T., Kawish, M., Maharjan, R., Ghaffar, I., Ali, H. S., Imran, M., Perveen, S., Saifullah, S.,
Simjee, S. U., & Shah, M. R. Design and development of permeation enhancer containing self-
nanoemulsifying drug delivery system (SNEDDS) for ceftriaxone sodium improved oral
pharmacokinetics. Journal of Molecular Liquids, 2019 Sep 1, 289, 111098.
Table 4.1: Software in ADME process.
Software Description
chemTree Predict ADME/toxicity properties
GRID Determine energetically favorable binding site
on molecules
MoKa In silico computation of pK
a
values
MDL metabolite database A complete metabolism information system
MDL toxicity database Structure-searchable bioactivity database of toxic
chemical substance
82 Sunil Kumar Kadiri, Dhritija Sathavalli, and Prashant Tiwari
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана